Eiger BioPharmaceuticals, Inc.
EIGRQ Healthcare Biotechnology
Eiger BioPharmaceuticals, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $15.8 million, up 17.0% from fiscal 2022. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow EIGRQ
Eiger BioPharmaceuticals, Inc. (EIGRQ) EV/Sales
As of 1 October 2024, Eiger BioPharmaceuticals, Inc. (EIGRQ) trades at a EV/Sales of 4.4×. Over the past ten years it has ranged from −2.6× (December 2022) to 23.8× (August 2022); the current reading is higher than 88% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 4.2× | — |
| FY2022 | −0.5× | — |
| FY2021 | 9.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2023 | 4.2× | 321.11% |
| Sep 2023 | 1.0× | (14.48%) |
| Jun 2023 | 1.2× | 272.70% |
| Mar 2023 | 0.3× | — |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELAB PMGC Holdings Inc. compare | −6.7× |
| GOVX GeoVax Labs Inc. compare | −0.3× |
| SLXN Silexion Therapeutics Corp compare | n/m |
| XRTX XORTX Therapeutics Inc. compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | 0.0× |
| EIGRQ Eiger BioPharmaceuticals, Inc. | 4.4× |
| VBIO Valion Bio, Inc. compare | 11.3× |
| NTBLQ Notable Labs, Ltd. compare | 23.3× |
| BIORQ Biora Therapeutics, Inc. compare | 67.4× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)